Fate Therapeutics, Inc.
FATE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$186,262 | -$160,928 | -$281,721 | -$212,151 |
| Dep. & Amort. | $18,962 | $18,282 | $13,758 | $5,850 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $54,364 |
| Change in WC | -$1,958 | $19,182 | -$34,710 | $2,098 |
| Other Non-Cash | $46,384 | -$8,799 | $54,465 | -$13,031 |
| Operating Cash Flow | -$122,874 | -$132,263 | -$248,208 | -$162,870 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$730 | -$6,153 | -$35,566 | -$50,704 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$317,750 | -$358,810 | -$404,796 | -$968,159 |
| Inv. Sales/Matur. | $330,698 | $477,628 | $607,113 | $694,840 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $12,218 | $112,665 | $166,751 | -$324,023 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $94,822 | $85 | $9,207 | $411,735 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $5,070 | $0 | $0 | $41,394 |
| Financing Cash Flow | $99,892 | $85 | $9,207 | $453,129 |
| Forex Effect | $4,950 | $50 | $0 | $0 |
| Net Chg. in Cash | -$5,814 | -$19,463 | -$72,250 | -$33,764 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $41,870 | $61,333 | $133,583 | $182,574 |
| End Cash | $36,056 | $41,870 | $61,333 | $148,810 |
| Free Cash Flow | -$123,604 | -$138,416 | -$283,774 | -$213,574 |